Page 3 of 26, showing 50 records out of 1263 total, starting on record 101, ending on 150
| Publication |
Category |
Year |
|
105. Luo, S., Martel, C., Leblanc, G., Candas, B., Singh, S.M., Labrie, C., Simard, J., Bélanger, A., Labrie, F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocrine-Related Cancer, 3: 229-241. |
All publications |
1996 |
|
106. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R.E., Diamond, P., Candas, B., Labrie, F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol., 20: 86-93. |
All publications |
1996 |
|
107. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. |
All publications |
1996 |
|
108. Bélanger, A., Van Halbeek, H., Graves, H.C.B., Grandbois, K., Stamey, T.A., Lihua, H., Poppe, I., Labrie, F. (1995) Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate, 27: 187-197. |
All publications |
1995 |
|
109. Chen, C., Puy, L.A., Simard, J., Li, X., Singh, S.M., Labrie, F. (1995) Local and systemic reduction by topical Finasteride or Flutamide on hamster flank organ size and enzyme activity. J. Invest. Dermatol., 105: 678-682. |
All publications |
1995 |
|
110. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab., 80: 1066-1071. |
All publications |
1995 |
|
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. |
All publications |
1995 |
|
112. Labrie, F., Crawford, D.; (1995) Anti-androgens in treatment of prostate cancer. Lancet, 346: 1030-1031. |
All publications |
1995 |
|
113. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Candas, B. (1995) Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J. Clin. Endocrinol. Metab., 80: 2002-2013. |
All publications |
1995 |
|
114. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Candas, B. (1995) Screening und Re-Screening des Prostatakarzinoms: Die Quebec-Studie, in Faul, P. et Altwein, J.E., eds: Screening des Prostatakarzinoms, Berlin, Springer-Verlag, pp 339-352. |
All publications |
1995 |
|
115. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1995) Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv. 23: 149-156. |
All publications |
1995 |
|
116. Li, X., Singh, S.M., Côté, J., Laplante, S., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro evaluation of 4-substituted-N-(1,1-dimethylethyl)-3-oxo-4-androsten-17beta-carboxamides as 5alpha-reductase inhibitors and antiendrogens. J. Med. Chem., 38: 1456-1461. |
All publications |
1995 |
|
117. Li, X., Singh, S.M., Labrie, F. (1995) Synthesis and in vitro activity of 17beta-(N-alkyl)formamido/ alkylamido-4-aza-/4-methyl-4-aza-3-oxo-5beta-androstan-3-ones as inhibitors of human 5alpha-reductase and antagonists on the androgen receptor. J. Med. Chem., 38: 1158-1173. |
All publications |
1995 |
|
118. Li, X., Singh, S.M., Lourdusamy, M., Mérand, Y., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro antiandrogenic activity of 17beta-hydroxy-17beta-(w-hydroxy/haloalkyn-1'-yl)-4-methyl-4-aza-3-oxo-5beta-androstan-(1-ene)-3-ones. Bioorg. Med. Chem. Lett., 5: 1061-1064. |
All publications |
1995 |
|
119. Narod, S., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Suburu, R., Labrie, F. (1995) The impact of family history on early detection of prostate cancer. Nature Medicine, 1: 99-101. |
All publications |
1995 |
|
120. Sun, S., Narod, S., Aprikian, A., Ghadirian, P., Labrie, F. (1995) Androgen receptor and familial prostate cancer. Nature Medicine, 1: 848-849. |
All publications |
1995 |
|
121. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Labrie, F. (1994) Changes in serum concentration of conjugated and unconjugated steroids in 40- to 80-year old men. J. Clin. Endocrinol. Metab., 79: 1086-1090. |
All publications |
1994 |
|
122. Cusan, L., Gomez, J.L., Dupont, A., Diamond, P., Lemay, M., Moore, S., Labrie, F. (1994) Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide. Prostate, 24: 257-261. |
All publications |
1994 |
|
123. Koutsilieris, M., Dupont, A., Gomez, J.L., Cusan, L., Suburu, R., Diamond, P., Labrie, F. (1994) Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal therapy (GnRH-A plus Flutamide). Anticancer Res., 14: 627-634. |
All publications |
1994 |
|
124. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. |
All publications |
1994 |
|
125. Labrie, F. (1994) Les antiandrogènes dans le cancer de la prostate. La Lettre du Pharmacologue, 8: 190-195. |
All publications |
1994 |
|
126. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to 342: 901-5, 1993]. Lancet, 343: 491. |
All publications |
1994 |
|
127. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to Cheney re 343: 491-2, 1994]. Lancet, 343: 976-977. |
All publications |
1994 |
|
128. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1994) Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29-37. |
All publications |
1994 |
|
129. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. |
All publications |
1994 |
|
130. Sugimoto, K., Simard, J., Veilleux, R., Haagensen, D.E., Labrie, F. (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J. Steroid Biochem. Mol. Biol., 51: 167-174. |
All publications |
1994 |
|
131. Bélanger, A., Rong, P.M., Liu, S., Lavoie, L., Labrie, F. (1993) Characterization and measurement of prostate-specific antigen using monoclonal antibodies. Clin. Invest. Med., 16: 409-415. |
All publications |
1993 |
|
132. Dupont, A., Cusan, L., Gomez, J.L., Koutsilieris, M., Suburu, R., Emond, J., Labrie, F. (1993) Combination therapy with Flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol., 72: 629-634. |
All publications |
1993 |
|
133. Dupont, A., Gomez, J.L., Cusan, L., Koutsilieris, M., Labrie, F. (1993) Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908-913. |
All publications |
1993 |
|
134. Labrie, F. (1993) GNRH agonists in prostate cancer, in GnRH analogues - The State of the Art 1993, New York, Parthenon Publishing, pp 103-121. |
All publications |
1993 |
|
135. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. |
All publications |
1993 |
|
136. Labrie, F. (1993) Mechanism of action and pure antiandrogenic properties of Flutamide. Cancer, 72: 3816-3827. |
All publications |
1993 |
|
137. Labrie, F. (1993) Non-steroidal antiandrogens, in: Droz, J.P., Cvitkovic, E., Armand, J.P. et Khoury, S., eds: Handook of Chemotherapy in Clinical Oncology, London, Scientific Communication International Ltd., pp 389-391. |
All publications |
1993 |
|
138. Labrie, F. (1993) Present status of endocrine therapy of prostate cancer. Eur. Urol. Today, 3: 10-11. |
All publications |
1993 |
|
139. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. |
All publications |
1993 |
|
140. Labrie, F., Bélanger, A., Simard, J., Labrie, C., Dupont, A. (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first line therapy. Cancer, 71: 1059-1067. |
All publications |
1993 |
|
142. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M., Tetu, B., Emond, J., Candas, B. (1993) Downstaging of localized prostate cancer by neoadjuvant therapy with Flutamide and Lupron. Clin. Invest. Med., 16: 499-509. |
All publications |
1993 |
|
143. Labrie, F., Dupont, A., Simard, J., Luu-The, V., Bélanger, A. (1993) Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol., 24 Suppl. 2: 94-105. |
All publications |
1993 |
|
144. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Gomez, J.L., Koutsilieris, M., Diamond, P., Emond, J., Lemay, M., Candas, B. (1993) Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin. Invest. Med., 16: 425-439. |
All publications |
1993 |
|
145. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1993) Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Mol. Cell. Endocrinol., 91: 43-49. |
All publications |
1993 |
|
146. Normand, T., Narod, S., Labrie, F., Simard, J. (1993) Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase II gene at the human EDH17B2 locus on 17q11-q21. Hum. Mol. Genet., 2: 479-483. |
All publications |
1993 |
|
147. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Suburu, E.R., Lemay, M., Labrie, F. (1992) Incidence of liver toxicity associated with the use of Flutamide in prostate cancer patients. Am. J. Med., 92: 465-470. |
All publications |
1992 |
|
148. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Tremblay, M., Labrie, F. (1992) Simultaneous liver and lung toxicity related to the non-steroidal antiandrogen Nilutamide (Anandron): a case report. Am. J. Med., 92: 563-566. |
All publications |
1992 |
|
149. Labrie, F. (1992) Stratégie efficace et peu coûteuse pour la détection du cancer de la prostate à un stade précoce alors que la guérison est possible. Médecine/Sciences, 8: 703-706. |
All publications |
1992 |
|
150. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1992) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer (8-year clinical experience) and extension to early stages of the diseases, in: Carpi, A., Sagripanti, A. et Mittermayer, eds: Progress in Clinical Oncology, Italy, Sympomed Verlag, pp 278-293. |
All publications |
1992 |
|
151. Labrie, F., Dupont, A., Cusan, L., Suburu, E.R., Gomez, J.L., Thibault, M.M., Tremblay, M. (1992) Perspectives dans le diagnostic et le traitement du cancer de la prostate au stade précoce, in: Bonjour, J.P., Gayraud, M.,Guillevin, L. et Rizzoli, R., eds: Nouvelles statégies thérapeutiques en cancérologie, rapports présentés au XLVIIIe Congrès Français de Médecine, Montréal 1991, Alertes carcinologiques, pp 25-44. |
All publications |
1992 |
|
152. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.L., Emond, J. (1992) Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J. Urol., 147: 846-851. |
All publications |
1992 |
|
153. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1992) Blockade of androgen action by combined treatment with a pure antiandrogen (Flutamide) and a 5α-reductase inhibitor (4-MA), in: Giuliani, L. et Puppo, P., eds: Urology, Bologna, Monduzzi Editore, pp 605-610. |
All publications |
1992 |
|
154. Pinault, S., Têtu, B., Gagnon, J., Monfette, G., Dupont, A., Labrie, F. (1992) Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination therapy with flutamide. Urology, 39: 254-261. |
All publications |
1992 |
|
155. Bélanger, A., Brochu, M., Lacoste, D., Noel, C., Labrie, F., Dupont, A., Cusan, L., Caron, S., Couture, J. (1991) Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J. Steroid Biochem. Mol. Biol., 40: 593-598. |
All publications |
1991 |